The majority of prostate cancers (PCa) and Castrate Resistant Prostate Cancers (CRPC) have functional AR, which continues to drive the expression of AR-dependent cell proliferative genes and hence the tumor growth despite of low level of systemic androgens [52, 53]. This evidence concerns the gene AR and prostate carcinoma.